In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...

Wall Street analysts forecast that Teva Pharmaceutical Industries Ltd. (TEVA) will report quarterly earnings of $0.64 per share in its upcoming release, pointing to a year-over-year decline of 9.9%.

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Why Teva’s Price Target Just Got Nudged Higher Teva Pharmaceutical Industries just saw its fair value estimate move from US$32.77 to US$33.86, with the discount rate held around 8.52% and revenue ...

Teva Pharmaceutical Industries recently reported third-quarter 2025 earnings that exceeded analysts’ expectations, advanced an FDA filing for an olanzapine long-acting injectable for schizophrenia, ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...

Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

Teva Pharmaceuticals can’t delay the first trial in thousands of lawsuits over claims its Paragard intrauterine contraceptive ...